Rate versus rhythm control and outcomes in patients with atrial fibrillation and chronic kidney disease: Data from the GUSTO-III trial

Cardiology Journal

Volumn 20, Issue 4, 2013, Pages 439-446

  Williams, Eric S ^a   Thompson, Vivian P ^b   Chiswell, Karen E ^b   Alexander, John H ^b   White, Harvey D ^c   Ohman, E Magnus ^b   Al Khatib, Sana M ^b  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Antiarrhythmic medications; Atrial fibrillation; Chronic kidney disease; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTITHROMBOCYTIC AGENT; CREATININE; DISOPYRAMIDE; FLECAINIDE; HEPARIN; PROCAINAMIDE; PROPAFENONE; QUINIDINE; RETEPLASE; SOTALOL; WARFARIN;

AGED; ARTICLE; CARDIOVERSION; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINUS RHYTHM; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CHI-SQUARE DISTRIBUTION; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ELECTRIC COUNTERSHOCK; FEMALE; HEART RATE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; ODDS RATIO; PATIENT DISCHARGE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84885192238     PISSN: 18975593     EISSN: 1898018X     Source Type: Journal    
DOI: 10.5603/CJ.2013.0104     Document Type: Article

References (23)

1. Reinecke H, Brand E, Mesters R et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol, 2009; 20: 705-711.
2. Soliman EZ, Prineas RJ, Go AS et al. Chronic kidney disease and prevalent atrial fibrillation: The Chronic Renal Insufficiency Cohort (CRIC). Am Heart J, 2010; 159: 1102-1107.
3. McManus DD, Corteville DC, Shlipak MG et al. Relation of kidney function and albuminuria with atrial fibrillation (from the Heart and Soul Study). Am J Cardiol, 2009; 104: 1551-1555.
4. Wong CK, White HD, Wilcox RG et al. New atrial fibrillation after acute myocardial infarction independently predicts death: The GUSTO-III experience. Am Heart J, 2000; 140: 878-885.
5. Nilsson KR, Jr., Al-Khatib SM, Zhou Y et al. Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. Heart, 2010; 96: 838-842.
6. Wong CK, White HD, Wilcox RG et al. Management and outcome of patients with atrial fibrillation during acute myocardial infarction: The GUSTO-III experience. Global use of strategies to open occluded coronary arteries. Heart, 2002; 88: 357-362.
7. Smith GL, Masoudi FA, Shlipak MG et al. Renal impairment predicts long-term mortality risk after acute myocardial infarction. J Am Soc Nephrol, 2008; 19:141-150.
8. Shlipak MG, Heidenreich PA, Noguchi H et al. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med, 2002; 137: 555-562.
9. A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. N Engl J Med, 1997; 337: 1118-1123.
10. Crenshaw BS, Ward SR, Granger CB et al. Atrial fibrillation in the setting of acute myocardial infarction: The GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol, 1997; 30: 406-413.
11. Kober L, Swedberg K, McMurray JJ et al. Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. Eur J Heart Fail, 2006; 8: 591-598.
12. Al-Khatib SM, Pieper KS, Lee KL et al. Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: results from the PURSUIT trial. Am J Cardiol, 2001; 88: A7, 76-79.
13. Pedersen OD, Abildstrom SZ, Ottesen MM et al. Increased risk of sudden and non-sudden cardiovascular death in patients with atrial fibrillation/flutter following acute myocardial infarction. Eur Heart J, 2006; 27: 290-295.
14. Julian DG, Camm AJ, Frangin G et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet, 1997; 349: 667-674.
15. Pedersen OD, Bagger H, Kober L et al. The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution. Eur Heart J, 1999; 20: 748-754.
16. Watanabe H, Watanabe T, Sasaki S et al. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: The Niigata preventive medicine study. Am Heart J, 2009; 158: 629-636.
17. Baber U, Howard VJ, Halperin JL et al. Association of Chronic Kidney Disease With Atrial Fibrillation Among Adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Electrophysiol, 2011; 4: 26-32.
18. Al Suwaidi J, Reddan DN, Williams K et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation, 2002; 106: 974-980.
19. Gibson CM, Dumaine RL, Gelfand EV et al. Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. Eur Heart J, 2004; 25: 1998-2005.
20. Rodrigues FB, Bruetto RG, Torres US et al. Effect of kidney disease on acute coronary syndrome. Clin J Am Soc Nephrol, 2010; 5: 1530-1536.
21. Denetclaw TH, Oshima N, Dowling TC. Dofetilide dose calculation errors in elderly associated with use of the modification of diet in renal disease equation. Ann Pharmacother, 2011; 45: e44.
22. Patane S, Marte F, Di Bella G et al. QT interval prolongation, torsade de pointes and renal disease. Int J Cardiol, 2008; 130: e71-e73.
23. Kestenbaum B, Rudser KD, Shlipak MG et al. Kidney function, electrocardiographic findings, and cardiovascular events among older adults. Clin J Am Soc Nephrol, 2007; 2: 501-508.